NovoCure Statistics
Want to see NVCR full AI Analyst Report?
NovoCure (NVCR) Stock Statistics & Valuation Metrics
Total Valuation
NovoCure has a market cap or net worth of $1.30B. The enterprise value is $1.62B.
- Market Cap
- $1.30B
- Enterprise Value
- $1.62B
Share Statistics
NovoCure has 116,915,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 116,915,960
- Owned by Insiders
- 2.70%
- Owned by Institutions
- 65.28%
Financial Efficiency
NovoCure’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -25.94%.
- Return on Equity (ROE)
- -0.40
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -25.94%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 408.32K
- Profits Per Employee
- -84.88K
- Employee Count
- 1,605
- Asset Turnover
- 0.81
- Inventory Turnover
- 4.06
Valuation Ratios
The current PE Ratio of NovoCure is -10.46. NovoCure’s PEG ratio is -0.40.
- PE Ratio
- -10.46
- PS Ratio
- 1.79
- PB Ratio
- 3.69
- Price to FCF
- -63.85
- Price to Operating Cash Flow
- 360.90
- PEG Ratio
- -0.40
Income Statement
In the last 12 months, NovoCure had revenue of 655.35M and earned -136.23M in profits. Earnings per share was -1.22.
- Revenue
- 655.35M
- Gross Profit
- 488.47M
- Operating Income
- -153.80M
- Pretax Income
- -136.25M
- Net Income
- -136.23M
- EBITDA
- -121.60M
- Earnings Per Share (EPS)
- -1.22
Cash Flow
In the last 12 months, operating cash flow was 3.59M and capital expenditures -23.89M, giving a free cash flow of -20.30M billion.
- Operating Cash Flow
- 3.59M
- Free Cash Flow
- -20.30M
- Free Cash Flow per Share
- -0.17
Dividends & Yields
NovoCure pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.56%
- Earnings Yield
- -9.36%
Stock Price Statistics
- Beta
- 1.22
- 52-Week Price Change
- -1.15%
- 50-Day Moving Average
- 14.84
- 200-Day Moving Average
- 14.83
- Relative Strength Index (RSI)
- 29.88
- Average Volume (3m)
- 1.53M
Important Dates
NovoCure upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
NovoCure as a current ratio of 2.90, with Debt / Equity ratio of 85.18%
- Current Ratio
- 2.90
- Quick Ratio
- 2.71
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- -1.53
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NovoCure has paid -23.00K in taxes.
- Income Tax
- -23.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
NovoCure EV to EBITDA ratio is -13.79, with an EV/FCF ratio of -70.81.
- EV to Sales
- 1.98
- EV to EBITDA
- -13.79
- EV to Free Cash Flow
- -70.81
- EV to Operating Cash Flow
- 400.69
Balance Sheet
NovoCure has $463.48M in cash and marketable securities with $231.55M in debt, giving a net cash position of $231.93M billion.
- Cash & Marketable Securities
- $463.48M
- Total Debt
- $231.55M
- Net Cash
- $231.93M
- Net Cash Per Share
- $1.98
- Tangible Book Value Per Share
- $3.00
Margins
Gross margin is 77.02%, with operating margin of -17.17%, and net profit margin of -16.78%.
- Gross Margin
- 77.02%
- Operating Margin
- -17.17%
- Pretax Margin
- -18.00%
- Net Profit Margin
- -16.78%
- EBITDA Margin
- -14.37%
- EBIT Margin
- -16.72%
Analyst Forecast
The average price target for NovoCure is $23.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $23.75
- Price Target Upside
- 113.20% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 12.94%
- EPS Growth Forecast
- 33.87%
Scores
- Smart Score
- 4
- AI Score
- 49

